# CRBU — slm-full-gpu

## Metadata

ticker: CRBU
arm: slm-full-gpu
judge_prompt_version: v2
context_sha256: 3d6e9403b93bebc7c809c0f30dc6b96ceebfa3f6d3692701e3d36db348c16bfd
slm_endpoint: slm-gpu
slm_url: http://132.145.161.150:30880
slm_served_name: qwen3.6-35b-a3b-q4km
slm_artifact: ggml-org/Qwen3.6-35B-A3B-GGUF@baec3ebee244827cda0f4557eafa8b28f7545fa6:Qwen3.6-35B-A3B-Q4_K_M.gguf sha256:671e47e0ec53c665d048b98c3ecbfd5236b5ca9c3e02ed19fc8f81f7b85140c7
slm_build: b11347-5fc4f3c8c
slm_model_path: /models/Qwen3.6-35B-A3B-Q4_K_M.gguf
slm_model_ftype: Q4_K - Medium
slm_total_slots: 4
slm_n_ctx: 32768
slm_n_params: 34660610688
slm_model_size_bytes: 20408576512
slm_thinking: off
slm_sampling: {"planner": {"chat_template_kwargs": {"enable_thinking": false}, "dry_multiplier": 0.0, "frequency_penalty": 0.0, "max_tokens": 1024, "min_p": 0.0, "presence_penalty": 0.0, "repeat_penalty": 1.0, "temperature": 0.0, "top_k": 20, "top_n_sigma": -1.0, "top_p": 0.8, "typical_p": 1.0, "xtc_probability": 0.0}, "rag": {"chat_template_kwargs": {"enable_thinking": false}, "dry_multiplier": 0.0, "frequency_penalty": 0.0, "max_tokens": 2048, "min_p": 0.0, "presence_penalty": 0.0, "repeat_penalty": 1.0, "temperature": 0.1, "top_k": 20, "top_n_sigma": -1.0, "top_p": 0.8, "typical_p": 1.0, "xtc_probability": 0.0}, "react": {"chat_template_kwargs": {"enable_thinking": false}, "dry_multiplier": 0.0, "frequency_penalty": 0.0, "max_tokens": 1024, "min_p": 0.0, "presence_penalty": 0.0, "repeat_penalty": 1.0, "temperature": 0.0, "top_k": 20, "top_n_sigma": -1.0, "top_p": 0.8, "typical_p": 1.0, "xtc_probability": 0.0}, "section": {"chat_template_kwargs": {"enable_thinking": false}, "dry_multiplier": 0.0, "frequency_penalty": 0.0, "max_tokens": 768, "min_p": 0.0, "presence_penalty": 0.0, "repeat_penalty": 1.0, "temperature": 0.1, "top_k": 20, "top_n_sigma": -1.0, "top_p": 0.8, "typical_p": 1.0, "xtc_probability": 0.0}, "synthesis": {"chat_template_kwargs": {"enable_thinking": false}, "dry_multiplier": 0.0, "frequency_penalty": 0.0, "max_tokens": 4096, "min_p": 0.0, "presence_penalty": 0.0, "repeat_penalty": 1.0, "temperature": 0.2, "top_k": 20, "top_n_sigma": -1.0, "top_p": 0.8, "typical_p": 1.0, "xtc_probability": 0.0}}
llm_calls: 7
llm_endpoints: slm-gpu
llm_by_site: {"rag:highlights": {"calls": 1, "completion_tokens": 557, "completion_tokens_unrecorded": 0, "errors": 0, "format_failure": 0, "latency_s_max": 20.957, "latency_s_total": 20.957, "parse_failure": 0, "prompt_tokens": 3132, "prompt_tokens_unrecorded": 0, "repeat_run": 0, "retry": 0, "truncated": 0}, "rag:risks": {"calls": 1, "completion_tokens": 533, "completion_tokens_unrecorded": 0, "errors": 0, "format_failure": 0, "latency_s_max": 18.528, "latency_s_total": 18.528, "parse_failure": 0, "prompt_tokens": 3121, "prompt_tokens_unrecorded": 0, "repeat_run": 0, "retry": 0, "truncated": 0}, "section:financial_health": {"calls": 1, "completion_tokens": 131, "completion_tokens_unrecorded": 0, "errors": 0, "format_failure": 0, "latency_s_max": 3.439, "latency_s_total": 3.439, "parse_failure": 0, "prompt_tokens": 687, "prompt_tokens_unrecorded": 0, "repeat_run": 0, "retry": 0, "truncated": 0}, "section:recent_developments": {"calls": 1, "completion_tokens": 155, "completion_tokens_unrecorded": 0, "errors": 0, "format_failure": 0, "latency_s_max": 13.127, "latency_s_total": 13.127, "parse_failure": 0, "prompt_tokens": 681, "prompt_tokens_unrecorded": 0, "repeat_run": 0, "retry": 0, "truncated": 0}, "section:risk_factors": {"calls": 1, "completion_tokens": 193, "completion_tokens_unrecorded": 0, "errors": 0, "format_failure": 0, "latency_s_max": 9.313, "latency_s_total": 9.313, "parse_failure": 0, "prompt_tokens": 609, "prompt_tokens_unrecorded": 0, "repeat_run": 0, "retry": 0, "truncated": 0}, "section:sec_filing_highlights": {"calls": 1, "completion_tokens": 155, "completion_tokens_unrecorded": 0, "errors": 0, "format_failure": 0, "latency_s_max": 7.995, "latency_s_total": 7.995, "parse_failure": 0, "prompt_tokens": 641, "prompt_tokens_unrecorded": 0, "repeat_run": 0, "retry": 0, "truncated": 0}, "synthesis": {"calls": 1, "completion_tokens": 952, "completion_tokens_unrecorded": 0, "errors": 0, "format_failure": 0, "latency_s_max": 28.259, "latency_s_total": 28.259, "parse_failure": 0, "prompt_tokens": 1654, "prompt_tokens_unrecorded": 0, "repeat_run": 0, "retry": 0, "truncated": 0}}

## Retrieved source context

STOCK DATA:
{
  "ticker": "CRBU",
  "company_name": "Caribou Biosciences, Inc.",
  "current_price": 0.6174,
  "currency": "USD",
  "market_cap": 66189916.0,
  "forward_pe": -0.4887084,
  "week_52_high": 3.535,
  "week_52_low": 0.546,
  "financial_currency": "USD",
  "revenue": 10035000.0,
  "net_income": -103403000.0,
  "profit_margin_pct": 0.0,
  "dividend_yield": 0.0,
  "sector": "Healthcare",
  "industry": "Biotechnology"
}

NEWS ARTICLES:
[
  {
    "title": null,
    "source": null,
    "published_at": null,
    "description": null
  }
]

SEC FILING SUMMARIES:
{
  "10-K": {
    "form_type": "10-K",
    "filing_date": "2026-03-05",
    "summary": "Item 1A. Risk Factors. Investing in shares of our common stock involves a high degree of risk. You should carefully consider the following risks and uncertainties, together with all of the other information contained in this Annual Report on Form 10-K, including our financial statements and related notes, before making an investment decision. These disclosures reflect our beliefs and opinions as to factors that could materially and adversely affect our company and its securities in the future. References to past events are provided by way of example only and are not intended to be a complete listing or a representation as to whether or not such factors have occurred in the past or their likelihood of occurring in the future. Furthermore, the risks described below are not the only ones faci"
  },
  "10-Q": {
    "form_type": "10-Q",
    "filing_date": "2026-08-13",
    "summary": "Item 1A. Risk Factors. There have been no material changes to the Risk Factors previously disclosed in Item 1A. to Part I of our Form 10-K. The risks described in our Form 10-K are not the only risks facing our company. Additional risks and uncertainties not currently known to us or that we currently deem to be immaterial also may materially adversely affect our business, financial condition, and/or operating results. Item 2. Unregistered Sales of Equity Securities, Use of Proceeds, and Issuer Purchases of Equity Securities. Unregistered Sales of Equity Securities during the Three Months Ended June 30, 2026 There were no unregistered sales of equity securities during the three months ended June 30, 2026. Item 5. Other Information. During the quarter ended June 30, 2026, none of our directo"
  }
}

RAG — SEC HIGHLIGHTS:
[From Pinecone cache] Based on the provided text from the Annual Report on Form 10-K for ticker CRBU, here are the key takeaways regarding the company's financial position and risks:

**Financial Performance and Status**
*   **Significant Operating Losses:** The company has incurred significant operating losses every year since its inception. Net losses were $148.1 million for the year ended December 31, 2025, and $149.1 million for the year ended December 31, 2024.
*   **Accumulated Deficit:** As of December 31, 2025, the company had an accumulated deficit of $596.5 million.
*   **No Revenue:** The company has not commercialized any products and has never generated revenue from product sales. Almost all financial resources have been devoted to research and development, including preclinical and clinical activities.

**Capital Requirements and Liquidity**
*   **Need for Additional Financing:** The company will need substantial additional financing to conduct its planned pivotal clinical trial for vispa-cel and to implement operating plans for its product candidates, vispa-cel and CB-011.
*   **Current Cash Position:** As of December 31, 2025, the company held $142.8 million in cash, cash equivalents, and marketable securities. This is expected to fund current operations for at least the next 12 months, though this expectation relies on assumptions that may prove incorrect.
*   **Insufficient Funds for Pivotal Trial:** The company currently does not have sufficient funds to conduct the planned pivotal clinical trial for vispa-cel. Failure to raise additional capital would prevent the initiation of this trial or the development of CB-011 beyond dose expansion.

**Future Expenses and Risks**
*   **Increasing Costs:** Expenses are expected to increase substantially as the company progresses clinical trials, hires employees, expands manufacturing capabilities, seeks regulatory approvals, and potentially establishes sales and marketing infrastructure.
*   **Unpredictability:** The company cannot predict the extent of future losses or when it might become profitable, if at all. Even if profitable, sustaining or increasing profitability is not guaranteed.
*   **Risk Factors:** Additional capital needs depend on various factors, including clinical trial results, regulatory delays, costs of intellectual property maintenance, litigation, and the need to establish internal manufacturing capabilities.
*   **Consequences of Funding Failure:** If the company fails to obtain additional financing, it will be unable to complete the development and commercialization of its product candidates. Additionally, fundraising efforts may divert management attention from day-to-day activities.

RAG — RISK FACTORS:
[From Pinecone cache] The primary risk factors disclosed include:

*   **Financial Position and Need for Additional Capital:** The company has incurred significant operating losses since inception, with net losses of $148.1 million in 2025 and $149.1 million in 2024, resulting in an accumulated deficit of $596.5 million as of December 31, 2025. The company has never generated revenue from product sales and anticipates continued operating losses for the foreseeable future.
*   **Inability to Achieve Profitability:** The company is unable to predict when it will become profitable, if at all, and may not be able to sustain or increase profitability even if it does become profitable.
*   **Need for Substantial Financing:** The company requires substantial additional financing to conduct its planned pivotal clinical trial for vispa-cel and to implement operating plans for CB-011. As of December 31, 2025, the company had $142.8 million in cash, cash equivalents, and marketable securities, which is expected to fund operations for at least the next 12 months, but this expectation is based on assumptions that may prove wrong.
*   **Failure to Obtain Financing:** If the company fails to obtain additional financing, it will be unable to complete the development and commercialization of its vispa-cel and/or CB-011 product candidates. Specifically, without additional funds, the company cannot initiate the pivotal clinical trial for vispa-cel or develop CB-011 beyond dose expansion.
*   **High Costs of Development and Commercialization:** Costs increase substantially as product candidates advance through clinical phases with greater numbers of patients. The company expects significant expenses related to clinical trials, manufacturing, regulatory approvals, intellectual property, hiring, and potentially establishing sales, marketing, and distribution infrastructure.
*   **Operational and Regulatory Risks:** Risks include delays or failures in clinical trials, safety issues, regulatory challenges, difficulties in receiving regulatory clearances, and the need to establish manufacturing capabilities and supply chains.
*   **Litigation and Public Company Costs:** The company faces risks associated with operating as a public company, including defending against securities class action litigation and other legal costs.
*   **Management Distraction:** Additional fundraising efforts may divert management from day-to-day activities, adversely affecting the ability to develop and commercialize product candidates.
*   **Uncertainty of Funding Availability:** The company cannot be certain that additional funding will be available when needed, on acceptable terms, or at all.

## Pre-written sections (judge input)

### Financial Health

Caribou Biosciences, Inc. (CRBU) currently trades at $0.6174 with a market capitalization of approximately $66.2 million. The company reported revenue of $10.04 million but incurred a net loss of $103.4 million, resulting in a negative profit margin and an ineffective forward P/E ratio. This significant net loss highlights the substantial cash burn typical of early-stage biotechnology firms focused on R&D. Consequently, the stock remains near its 52-week low of $0.546, reflecting investor caution regarding near-term profitability.

### Recent Developments

Caribou Biosciences continues to face significant financial headwinds, evidenced by a net loss of $103.4 million and a market capitalization hovering near $66 million. The company’s stock has traded within a narrow range between $0.546 and $3.535 over the past year, currently trading at $0.6174, reflecting sustained investor caution. Recent SEC filings, including the 10-K and 10-Q reports, highlight persistent risk factors without noting material changes to the business model or unregistered equity sales. For investors, these developments underscore the high-risk nature of the position, characterized by negative profitability and limited near-term catalysts visible in current disclosures.

### SEC Filing Highlights
Caribou Biosciences reported a net loss of $148.1 million for the year ended December 31, 2025, maintaining its status as a pre-revenue company with an accumulated deficit of $596.5 million. While the firm held $142.8 million in cash and equivalents as of year-end, management explicitly stated that these funds are insufficient to conduct the planned pivotal clinical trial for vispa-cel. Consequently, the company faces a critical need for substantial additional financing to advance its product candidates, vispa-cel and CB-011, beyond current development stages. Failure to secure this capital would prevent the initiation of pivotal trials and halt further development efforts.

### Risk Factors

*   **Substantial Financial Losses and Capital Requirements:** The company has incurred significant operating losses (accumulated deficit of $596.5 million as of Dec 31, 2025) and has never generated revenue; it requires substantial additional financing to fund pivotal trials for vispa-cel and CB-011, with current cash reserves only covering operations for approximately the next 12 months.
*   **Uncertainty of Future Profitability and Funding:** There is no guarantee the company will ever achieve profitability, and it cannot be certain that additional capital will be available when needed, on acceptable terms, or at all, which could halt development and commercialization efforts.
*   **High Development Costs and Operational Risks:** Advancing product candidates involves escalating costs for clinical trials, manufacturing, and regulatory approvals, alongside risks of trial delays, safety issues, and management distraction due to fundraising activities.

## Audited (Exec Summary + Outlook)

### Executive Summary
Caribou Biosciences is a pre-revenue biotechnology firm leveraging CRISPR technology to develop product candidates like vispa-cel and CB-011, currently operating with a $142.8 million cash reserve against a massive $596.5 million accumulated deficit. The stock is notable for its proximity to the 52-week low of $0.546, reflecting intense investor caution regarding the company’s ability to sustain operations and fund pivotal trials without dilutive capital raises. The single most important near-term variable is the company’s success in securing substantial additional financing, as current cash levels are explicitly insufficient to initiate the planned pivotal clinical trial for vispa-cel.

### Outlook
The directional outlook for Caribou Biosciences is cautiously negative, driven by the immediate liquidity constraint and the binary nature of its upcoming financing needs. Key variables to monitor include the timing and terms of any equity raises or partnerships, as well as the regulatory pathway clarity for vispa-cel and CB-011. The thesis would weaken significantly if the company fails to secure adequate capital within the next 12 months, potentially forcing a halt to development or severe dilution. Conversely, the view would strengthen only upon the successful closure of substantial financing that explicitly enables the initiation of pivotal trials, thereby de-risking the near-term operational timeline.

---
*This brief is for informational purposes only and does not constitute financial advice.*

## Judge findings

I will now systematically evaluate every specific quantitative figure, price target, threshold, ratio, metric, percentage, named product milestone, or forward-looking number in the Executive Summary and Outlook sections.

---

**EXECUTIVE SUMMARY**

---

CLAIM: "$142.8 million cash reserve"
LABEL: SUPPORTED
REASON: The RAG SEC Highlights and Risk Factors sections both explicitly state "As of December 31, 2025, the company had $142.8 million in cash, cash equivalents, and marketable securities," and the SEC Filing Highlights pre-written section repeats this figure.

---

CLAIM: "$596.5 million accumulated deficit"
LABEL: SUPPORTED
REASON: The RAG SEC Highlights explicitly states "As of December 31, 2025, the company had an accumulated deficit of $596.5 million," confirmed in both RAG sections and the pre-written Risk Factors section.

---

CLAIM: "52-week low of $0.546"
LABEL: SUPPORTED
REASON: The stock data explicitly lists "week_52_low": 0.546, and the pre-written Financial Health and Recent Developments sections both cite this figure.

---

CLAIM: "current cash levels are explicitly insufficient to initiate the planned pivotal clinical trial for vispa-cel"
LABEL: SUPPORTED
REASON: The RAG SEC Highlights explicitly states "The company currently does not have sufficient funds to conduct the planned pivotal clinical trial for vispa-cel," and the pre-written SEC Filing Highlights section repeats this characterization.

---

**OUTLOOK**

---

CLAIM: "the next 12 months" (as the period within which failure to secure capital would weaken the thesis)
LABEL: INFERENCE
REASON: The source data states cash is "expected to fund current operations for at least the next 12 months," making the 12-month window a direct restatement of the disclosed operational runway, applied here as the relevant monitoring horizon.

---

CLAIM: "successful closure of substantial financing that explicitly enables the initiation of pivotal trials"
LABEL: SUPPORTED
REASON: The RAG SEC Highlights and Risk Factors both explicitly state that additional financing is required to initiate the pivotal clinical trial for vispa-cel, and the pre-written SEC Filing Highlights section repeats this condition verbatim in substance.

---

**SUMMARY TABLE**

| # | Claim | Label |
|---|-------|-------|
| 1 | $142.8 million cash reserve | SUPPORTED |
| 2 | $596.5 million accumulated deficit | SUPPORTED |
| 3 | 52-week low of $0.546 | SUPPORTED |
| 4 | Current cash explicitly insufficient for pivotal trial | SUPPORTED |
| 5 | "next 12 months" as the relevant risk horizon | INFERENCE |
| 6 | Financing must explicitly enable initiation of pivotal trials | SUPPORTED |

No quantitative claims in the Outlook section are UNSUPPORTED. The brief is notably conservative in its use of figures, drawing only on values present in the source data.
